• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Stephen A. Cannistra, MD


  • Christina Herold and Stephen A. Cannistra.Gynecologic Cancer. In: Dale DC, Federman DD, ed. American College of Physicians (ACP) Medicine, 2013 edition Scientific American Medicine.Scientific American Medicine..
  • Cannistra SA, Gershenson DM, Recht A.Ovarian Cancer, Peritoneal Carcinoma, and Fallopian Tube Carcinoma.In: Devita VT, Lawrence TS, Rosenberg SA, ed. Ovarian Cancer, Peritoneal Carcinoma, and Fallopian Tube Carcinoma. Cancer: Principles and Practice of Oncology, 10th Edition. Lippincott, Williams, and Wilkins..
  • Joyce Liu and Stephen A. Cannistra.Emerging Role for Bevacizumab in Combination with Chemotherapy for Patients with Platinum-Resistant Ovarian Cancer.
  • Liu JF, Cannistra SA.Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.J Clin Oncol. 2014 May 1;32(13):1287-9.
  • Goodwin PJ, Ballman KV, Small EJ, Cannistra SA.Evaluation of treatment benefit in Journal of Clinical Oncology.J Clin Oncol. 2013 Mar 20;31(9):1123-4.
  • Haller DG, Cannistra SA.Providing protocol information for journal of clinical oncology readers: what practicing clinicians need to know.J Clin Oncol. 2011 Mar 20;29(9):1091.
  • Verweij J, Disis ML, Cannistra SA.Phase I studies of drug combinations.J Clin Oncol. 2010 Oct 20;28(30):4545-6.
  • Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA.Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.J Clin Oncol. 2010 Aug 1;28(22):3555-61.
  • Cannistra SA.Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?.J Clin Oncol. 2010 Jul 1;28(19):3101-3.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.J Clin Oncol. 2009 Nov 20;27(33):5601-6.
  • Cannistra SA.Phase II Trials in Journal of Clinical Oncology.J Clin Oncol. 2009 Jul 1;27(19):3073-6.
  • Konstantinopoulos PA,Fountzilas E,Pillay K,Zerbini LF,Libermann TA,Cannistra SA,Spentzos D.Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.BMC Med Genomics. 2008;1:59.
  • Konstantinopoulos PA, Spentzos D, Cannistra SA.Gene-expression profiling in epithelial ovarian cancer.Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. Review.
  • Cannistra SA.Challenges and pitfalls of combining targeted agents in phase I studies.J Clin Oncol. 2008 Aug 1;26(22):3665-7.
  • Cannistra SA.BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.Clin Cancer Res. 2007 Dec 15;13(24):7225-7.
  • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.J Clin Oncol. 2007 Nov 20;25(33):5180-6.
  • Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS.IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.Endocr Relat Cancer. 2007 Sep;14(3):781-90.
  • Comander AH, Cannistra SA.A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.Int J Gynecol Cancer. 2008 Jan-Feb;18(1):51-8.
  • Cannistra SA.Performance of biopsies in clinical research.J Clin Oncol. 2007 Apr 10;25(11):1454-5.
  • Cannistra SA.Gynecologic oncology or medical oncology: what's in a name?.J Clin Oncol. 2007 Apr 1;25(10):1157-9.
  • Cannistra SA.Intraperitoneal chemotherapy comes of age.N Engl J Med. 2006 Jan 5;354(1):77-9.
  • Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.Unique gene expression profile based on pathologic response in epithelial ovarian cancer.J Clin Oncol. 2005 Nov 1;23(31):7911-8.
  • Berkenblit A, Cannistra SA.Advances in the management of epithelial ovarian cancer.J Reprod Med. 2005 Jun;50(6):426-38.
  • Cannistra SA.Cancer of the ovary.N Engl J Med. 2004 Dec 9;351(24):2519-29.
  • Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA.A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.Gynecol Oncol. 2004 Dec;95(3):624-31.
  • Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA.Gene expression signature with independent prognostic significance in epithelial ovarian cancer.J Clin Oncol. 2004 Dec 1;22(23):4648-58.
  • Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA.Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.Gynecol Oncol. 2003 Jun;89(3):486-93.
  • Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L.Progress in the management of gynecologic cancer: consensus summary statement.J Clin Oncol. 2003 May 15;21(10 Suppl):129-32.
  • Schumer ST, Cannistra SA.Granulosa cell tumor of the ovary.J Clin Oncol. 2003 Mar 15;21(6):1180-9.
  • Cannistra SA.Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?.J Clin Oncol. 2002 Mar 1;20(5):1158-60.
  • Raffel GD, Gravallese EM, Schwab P, Joseph JT, Cannistra SA.Diagnostic dilemmas in oncology: case 2. Dermatomyositis and ovarian cancer.J Clin Oncol. 2001 Dec 1;19(23):4341-3.
  • Smith WM, Zhou XP, Kurose K, Gao X, Latif F, Kroll T, Sugano K, Cannistra SA, Clinton SK, Maher ER, Prior TW, Eng C.Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases.Hum Genet. 2001 Aug;109(2):146-51.
  • Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C.Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.Am J Pathol. 2001 Jun;158(6):2097-106.
  • Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D.Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.J Immunol. 2000 Aug 1;165(3):1705-11.
  • Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.Gynecol Oncol. 2000 May;77(2):271-7.
  • Strobel T, Cannistra SA.Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.Gynecol Oncol. 1999 Jun;73(3):362-7.
  • Tai YT, Strobel T, Kufe D, Cannistra SA.In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene.Cancer Res. 1999 May 1;59(9):2121-6.
  • Strobel T, Tai YT, Korsmeyer S, Cannistra SA.BAD partly reverses paclitaxel resistance in human ovarian cancer cells.Oncogene. 1998 Nov 12;17(19):2419-27.
  • Cannistra SA, DeFranzo B, Niloff J, Ottensmeir C.Functional heterogeneity of CD44 molecules in ovarian cancer cell lines.Clin Cancer Res. 1995 Mar;1(3):333-42.
  • Strobel T, Kraeft SK, Chen LB, Cannistra SA.BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death.Cancer Res. 1998 Nov 1;58(21):4776-81.
  • Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA.BAX protein expression and clinical outcome in epithelial ovarian cancer.J Clin Oncol. 1998 Aug;16(8):2583-90.
  • Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB.Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.Int J Cancer. 1998 Aug 31;77(5):741-6.
  • Strobel T, Swanson L, Korsmeyer S, Cannistra SA.Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells.Oncogene. 1997 Jun 12;14(23):2753-8.
  • Strobel T, Swanson L, Cannistra SA.In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.Cancer Res. 1997 Apr 1;57(7):1228-32.
  • Strobel T, Swanson L, Korsmeyer S, Cannistra SA.BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway.Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14094-9.
  • Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA.Absence of constitutive EGF receptor activation in ovarian cancer cell lines.Br J Cancer. 1996 Aug;74(3):446-52.
  • Cannistra SA, Niloff JM.Cancer of the uterine cervix.N Engl J Med. 1996 Apr 18;334(16):1030-8.
  • Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM.Location of BRCA1 in human breast and ovarian cancer cells.Science. 1996 Apr 5;272(5258):123-6.
  • Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA.Estrogen receptor expression is a common feature of ovarian borderline tumors.Gynecol Oncol. 1996 Feb;60(2):301-7.
  • Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J.Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer.Gynecol Oncol. 1995 Aug;58(2):216-25.
  • Cannistra SA, Abu-Jawdeh G, Niloff J, Strobel T, Swanson L, Andersen J, Ottensmeier C.CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.J Clin Oncol. 1995 Aug;13(8):1912-21.
  • Cannistra SA, Ottensmeier C, Tidy J, DeFranzo B.Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes.Exp Hematol. 1994 Sep;22(10):996-1002.
  • Cannistra SA.Cancer of the ovary.N Engl J Med. 1993 Nov 18;329(21):1550-9.
  • Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C.Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.Cancer Res. 1993 Aug 15;53(16):3830-8.
  • Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M.Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.J Clin Oncol. 1993 Aug;11(8):1583-91.